Novartis’ Gilyena Fails Phase III INFORMS Study

December 1, 2014 12:15 PM

12 0

People in the multiple sclerosis community may be a little disappointed today as pharmaceutical giant Novartis just posted quite discouraging news about their new drug which was designed to treat the complex condition of MS.

The drug, Gilenya (fingolimod) made it all the way to phase III clinical trial, but its INFORMS study only demonstrated that it would offer not better benefit than a placebo in patients dealing with primary progressive multiple sclerosis (PPMS). This is a specific form of multiple sclerosis which is...

Read more

To category page